- Home
- DRIO vs INKT Comparison
DRIO vs INKT Comparison
Compare DRIO & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRIO
- INKT
- Stock Information
- Founded
- DRIO 2011
- INKT 2017
- Country
- DRIO United States
- INKT United States
- Employees
- DRIO N/A
- INKT N/A
- Industry
- DRIO Medical/Dental Instruments
- INKT Medicinal Chemicals and Botanical Products
- Sector
- DRIO Health Care
- INKT Health Care
- Exchange
- DRIO Nasdaq
- INKT Nasdaq
- Market Cap
- DRIO 30.5M
- INKT 28.9M
- IPO Year
- DRIO N/A
- INKT 2021
- Fundamental
- Price
- DRIO $0.71
- INKT $7.22
- Analyst Decision
- DRIO Strong Buy
- INKT Strong Buy
- Analyst Count
- DRIO 2
- INKT 2
- Target Price
- DRIO $2.50
- INKT $37.50
- AVG Volume (30 Days)
- DRIO 168.4K
- INKT 15.0K
- Earning Date
- DRIO 08-07-2025
- INKT 08-12-2025
- Dividend Yield
- DRIO N/A
- INKT N/A
- EPS Growth
- DRIO N/A
- INKT N/A
- EPS
- DRIO N/A
- INKT N/A
- Revenue
- DRIO $28,034,000.00
- INKT N/A
- Revenue This Year
- DRIO $13.66
- INKT N/A
- Revenue Next Year
- DRIO $24.50
- INKT N/A
- P/E Ratio
- DRIO N/A
- INKT N/A
- Revenue Growth
- DRIO 47.20
- INKT N/A
- 52 Week Low
- DRIO $0.50
- INKT $4.56
- 52 Week High
- DRIO $1.55
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- DRIO 44.44
- INKT 47.31
- Support Level
- DRIO $0.67
- INKT $6.91
- Resistance Level
- DRIO $0.73
- INKT $8.38
- Average True Range (ATR)
- DRIO 0.04
- INKT 0.31
- MACD
- DRIO -0.00
- INKT -0.01
- Stochastic Oscillator
- DRIO 38.46
- INKT 20.98
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.